Back to results
US 2022/0177567 A1Published application
Anti-il12rb1 antibodies
AssigneeWashington University
InventorsMarco Colonna, Cristiane Secca da Silva
Life of this patent
Estimating the term…
Abstract
The present invention is directed towards isolated antibodies that bind to IL12Rβ1. Specifically, anti-IL12Rβ1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.
Claims20
An isolated anti-IL-12Rβ1 antibody comprising a light chain variable region comprising an L1 of SEQ ID NO:
- 4, an L2 of YTS, an L3 of SEQ ID NO:
- 5, or any combination thereof;
- and/or a heavy chain variable region comprising an H1 of SEQ ID NO:
- 1, an H2 of SEQ ID NO:
- 2, an H3 of SEQ ID NO:
- 3, or any combination thereof.
3 more elements
Dependencies are inferred from the claim text.